3 Dividend Stocks to Buy and Hold for the Next 5 Years

The article argues a cyclical trough may be near: Home Depot’s Q2 same-store sales rose just 1.7% (1.3% in the U.S.) as housing starts/completions sit near multiyear lows, but the piece cites a potential 4–5M-home demand gap and a forward dividend yield of ~2.8%. McDonald’s also shows weak demand signals with companywide same-store sales up only 1.3% YoY and U.S. up 0.8%, though management is pushing to boost baseline guest traffic and the stock is down >20% from a February peak; its forward dividend yield is cited at ~2.8% with a 49-year dividend-growth streak. Johnson & Johnson is framed as a reinvention story—targeting oncology revenue growth from ~$30B to $50B+ by 2030—and the FDA cleared Monarch bronchoscopy software, supporting a more constructive outlook despite a lower forward yield of ~2%.

Analysis

Home Depot is more of a timing call than a fundamental turn. The upside window opens only when mortgage rates and existing-home turnover improve enough to create real ticket-size leverage; until then, the stock likely trades like a slow-growth defensive with limited multiple expansion. The cleaner second-order beneficiary of a housing inflection is not just HD but also LOW, SHW, and flooring/cabinet suppliers where volume can rebound faster than headline sales.

McDonald’s looks less like a recession winner and more like a traffic-restoration story. If value positioning requires more discounting, franchisee economics get pinched first, and then the pain bleeds into the broader QSR cohort as peers are forced to defend share. The contrarian risk is that consumer strain may be more persistent than the market expects, so a fast bounce is only credible if U.S. guest counts turn positive and price no longer does the heavy lifting.

Johnson & Johnson is the highest-quality setup because the market can underwrite the cash flow today while optionally re-rating the growth story over 6-18 months. The oncology buildout and medtech software cadence create multiple expansion potential if execution persists; the main risk is that investors have to wait too long for the pipeline to become visible, in which case JNJ stays bond-like rather than compounder-like. Consensus may be underestimating how much a successful reinvention can narrow the discount to higher-growth healthcare peers without taking balance-sheet risk.

Key Decisions for Investors

• Long JNJ on a 6-12 month horizon; add on pullbacks of 3-5% if oncology/medtech execution remains intact. Falsify if next 2 quarters fail to show mix improvement or if growth guidance does not step up.
• Watchlist, not buy-now: HD only if housing data inflects and rates move lower over the next 1-3 months. Best expression is a rebound trade in HD/LOW versus suppliers leveraged to remodel activity (SHW/MAS) if starts trough.
• Avoid chasing MCD until traffic improves; if U.S. comps stay sub-1% excluding price for another quarter, the stock remains a value trap risk. A reversal needs positive guest traffic, not just price/mix.
• Pair idea: long JNJ / short XBI for the next 3-6 months. Thesis is quality cash flow plus visible self-help versus a funding-sensitive biotech basket; exit if JNJ underperforms the sector after pipeline updates.